Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-α for Locally Advanced Cancers

Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

(2010) Carlo Riccardo Rossi et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

(2010) Vanesa Gregorc et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies

(2010) Christina Fotopoulou et al.   JOURNAL OF SURGICAL ONCOLOGY

Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient

(2009) Sylvie Bonvalot et al.   ANNALS OF SURGICAL ONCOLOGY

Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

(2009) I.M.E. Desar et al.   CANCER TREATMENT REVIEWS

Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

(2008) Robert H. El-Maraghi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Pharmacokinetics of Isolated Pelvic Perfusion

(2008) James F. Belliveau et al.   Surgical Oncology Clinics of North America